Dogwood Therapeutics Reports Third-Quarter 2026 Financial Results
The company says it completed its Phase 2b trial of Halneuron for chemotherapy-induced neuropathy; top-line results are expected in November 2026. Its Phase 2b long-term extension study is fully recruited, with 95 patients enrolled.
Completed the Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy, top-line results to be announced in November 2026 -- Phase 2b Long-Term Extension Study fully recruited, 95 patients enrolled, assessing Halneuron® reduction in pain over three months of treatment with Halneuron® -- Close…